US Partnership Deal With Owen Mumford Announced

The partnership between Forte Medical and Owen Mumford USA was launched today at the OCTANe Medical Innovation Technology Forum (MTIF) at Newport Beach, CA 28-29 October 2019. 

Introducing Peezy Midstream to the USA has long been an ambition of Forte Medical. Our disruptive and innovative MedTech called for a partner with experience, knowledge and a savvy mindset. We found that partner in Atlanta-based Owen Mumford USA whose reach covers the USA and Canada and is managed by Travis Shaw.

Owen Mumford has been at the forefront of medical device innovation for over 65 years, creating solutions that improve the delivery of healthcare and home health treatments for people around the world. Their products span devices that make blood testing more comfortable to solutions that make it easier to administer life-saving medication.

Owen Mumford’s experience in medical devices began in the 1950s when founders Ivan Owen and John Mumford established the company. The company have direct sales offices and a network of distribution partners serving customers in over 60 countries, and employ over 800 people across the Americas, Europe and Asia.  

“Owen Mumford USA is delighted to partner Forte Medical in North America and Canada,” says Travis Shaw. “Our team looks forward to expanding our mutual synergies. Research indicates that Peezy Midstream can add significant clinical and cost value to healthcare providers, a true win-win for all parties.”
 
Thanks to the Greater Irvine Chamber of Commerce for making this possible.

Antibiotics and urinary tract infections

Antibiotics, better tests, UTI: Guardian publishes Forte response

A rise in persistent UTIs could be linked to antibiotic crackdown appeared in The Guardian on Saturday 5th October. As usual, no-one mentioned accurate basic specimen collection, which can lead to unwarranted specimen quality variation, failed analysis and less-than-targeted prescribing. Giovanna Forte had something to say. Click here to read her published letter.

Forte Medical Review

A Year In Review – 2018

  • New evidence showing a 70% reduction in false positive dipped specimens
  • Extended uptake by the NHS
  • Investment including a JV to create a Smart Peezy
  • Sheena Byrom joining our Advisory Panel
  • Being recognised in the Sunday Times 2018 Maserati 100 list that celebrate British entrepreneurship

These have been a few of our highlights for 2018 – to read more, please click here

Gionvanni Forte at no. 10

To No 10 for the LS Industrial Strategy Reception

Today, Forte Medical’s Chief Executive Giovanna Forte attended the Life Sciences Industrial Strategy reception at No 10 Downing Street – creating the foundation for brilliant innovation and MedTech

Peezy Usability Study Forte Medical

Peezy Midstream Case Study at NHS NIHR Conference 2018

Back in March of this year, the NHS National Institute for Health Research contacted Forte Medical, asking for a case study demonstrating how their research has assisted the launch of Peezy Midstream.

A few months earlier the NIHR in conjunction with the West Midlands AHSN conducted a valuable Usability Study on our diagnostic device. Results were excellent and have assisted us with adoption training and reassurance to HCPs and patients alike that using Peezy Midstream is far, far easier than trying to deliver this elusive urine specimen any other way …

The case study presented by Giovanna Forte on 10th October 2018 was very well received and has already led to enquiries from Primary Care clinicians who can see the benefit of right-first-time diagnoses for UTI and other common conditions that can take up so much GP time when left untreated.

2018 NIHR Peezy Presentation

NIHR_PeezyMidstream-Case-Study

Urology testing Forte Medical

“Why We’re Looking For Cancer Clues In Urine”

Interesting research being undertaken by Barbara Guinn, Head of Biomedical Sciences, University of Hull in The Conversation.com.   “A urine test for ovarian cancer could increase survival rates from 20% to 90%.”

This is why it’s so important that the quality of specimens allows for right-first-time diagnosis and that appropriate treatment follows.